STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Clinical trials for STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Weekly chemo may be gentler for head and neck cancer patients
Disease control TerminatedThis study compares two ways of giving the chemotherapy drug cisplatin alongside radiation for people with advanced head and neck cancer. One group gets a high dose every three weeks, the other gets a lower dose weekly. The goal is to see if the weekly schedule causes fewer side …
Matched conditions: STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Radiation plus immunotherapy: a new hope for advanced head and neck cancer?
Disease control OngoingThis phase III trial compares the standard immunotherapy drug pembrolizumab alone versus pembrolizumab plus radiation therapy in 290 patients with metastatic head and neck cancer. The goal is to see if adding radiation improves overall survival. Participants receive pembrolizumab…
Matched conditions: STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for head and neck cancer: Three-Drug showdown after immunotherapy fails
Disease control OngoingThis study tests three different drug combinations in 430 adults with advanced head and neck cancer that has spread or returned after prior immunotherapy. The goal is to see if adding bevacizumab to standard chemo, or using atezolizumab plus bevacizumab, works better than the usu…
Matched conditions: STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo shows promise for tough head and neck cancers
Disease control OngoingThis study tests whether adding the experimental drug ipatasertib to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with head and neck cancer that has returned or spread. About 52 adults with incurable, advanced squamous cell carcinoma w…
Matched conditions: STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC